Cargando…

Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer

Breast cancer is the most common malignancy in women globally. The increasing worldwide incidence of this type of cancer illustrates the challenge it represents for healthcare providers. Therefore, new tumor markers are constantly being sought. The aim of this study was to assess plasma concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Będkowska, Grażyna E., Gacuta, Ewa, Zbucka-Krętowska, Monika, Ławicki, Paweł, Szmitkowski, Maciej, Lemancewicz, Adam, Motyka, Joanna, Kobus, Agnieszka, Chorąży, Monika, Paniczko, Marlena, Ławicki, Sławomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624052/
https://www.ncbi.nlm.nih.gov/pubmed/34830735
http://dx.doi.org/10.3390/jcm10225452
_version_ 1784606079354667008
author Będkowska, Grażyna E.
Gacuta, Ewa
Zbucka-Krętowska, Monika
Ławicki, Paweł
Szmitkowski, Maciej
Lemancewicz, Adam
Motyka, Joanna
Kobus, Agnieszka
Chorąży, Monika
Paniczko, Marlena
Ławicki, Sławomir
author_facet Będkowska, Grażyna E.
Gacuta, Ewa
Zbucka-Krętowska, Monika
Ławicki, Paweł
Szmitkowski, Maciej
Lemancewicz, Adam
Motyka, Joanna
Kobus, Agnieszka
Chorąży, Monika
Paniczko, Marlena
Ławicki, Sławomir
author_sort Będkowska, Grażyna E.
collection PubMed
description Breast cancer is the most common malignancy in women globally. The increasing worldwide incidence of this type of cancer illustrates the challenge it represents for healthcare providers. Therefore, new tumor markers are constantly being sought. The aim of this study was to assess plasma concentrations and the diagnostic power of VEGF in 100 patients with early-stage breast cancer, both before and after surgical treatment and during a three-year follow-up. The control groups included 50 subjects with benign breast tumors (fibroadenoma) and 50 healthy women. The VEGF concentration was determined using enzyme-linked immunosorbent assay (ELISA) and the CA 15-3 concentration was determined by chemiluminescent microparticle immunoassay (CMIA). We observed significantly higher preoperative plasma concentrations of VEGF and CA 15-3 in patients with breast cancer. VEGF, similar to CA 15-3, demonstrated high diagnostic utility in the assessment of the long-term efficacy of surgical removal of the tumor. Determinations of VEGF had the highest diagnostic usefulness in the detection of breast cancer recurrence (SE 40%, SP 92%, PPV 67%, NPV 79%). Additionally, the highest values of SE, NPV and AUC were observed during the combined analysis with CA 15-3 (60%; 84%; 0.7074, respectively). Our study suggests a promising diagnostic utility of VEGF in the early stages of breast cancer and in the evaluation of the efficacy of the surgical treatment of breast cancer as well as the detection of breast cancer recurrence, particularly in a combined analysis with CA 15-3 as a new diagnostic panel.
format Online
Article
Text
id pubmed-8624052
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86240522021-11-27 Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer Będkowska, Grażyna E. Gacuta, Ewa Zbucka-Krętowska, Monika Ławicki, Paweł Szmitkowski, Maciej Lemancewicz, Adam Motyka, Joanna Kobus, Agnieszka Chorąży, Monika Paniczko, Marlena Ławicki, Sławomir J Clin Med Article Breast cancer is the most common malignancy in women globally. The increasing worldwide incidence of this type of cancer illustrates the challenge it represents for healthcare providers. Therefore, new tumor markers are constantly being sought. The aim of this study was to assess plasma concentrations and the diagnostic power of VEGF in 100 patients with early-stage breast cancer, both before and after surgical treatment and during a three-year follow-up. The control groups included 50 subjects with benign breast tumors (fibroadenoma) and 50 healthy women. The VEGF concentration was determined using enzyme-linked immunosorbent assay (ELISA) and the CA 15-3 concentration was determined by chemiluminescent microparticle immunoassay (CMIA). We observed significantly higher preoperative plasma concentrations of VEGF and CA 15-3 in patients with breast cancer. VEGF, similar to CA 15-3, demonstrated high diagnostic utility in the assessment of the long-term efficacy of surgical removal of the tumor. Determinations of VEGF had the highest diagnostic usefulness in the detection of breast cancer recurrence (SE 40%, SP 92%, PPV 67%, NPV 79%). Additionally, the highest values of SE, NPV and AUC were observed during the combined analysis with CA 15-3 (60%; 84%; 0.7074, respectively). Our study suggests a promising diagnostic utility of VEGF in the early stages of breast cancer and in the evaluation of the efficacy of the surgical treatment of breast cancer as well as the detection of breast cancer recurrence, particularly in a combined analysis with CA 15-3 as a new diagnostic panel. MDPI 2021-11-22 /pmc/articles/PMC8624052/ /pubmed/34830735 http://dx.doi.org/10.3390/jcm10225452 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Będkowska, Grażyna E.
Gacuta, Ewa
Zbucka-Krętowska, Monika
Ławicki, Paweł
Szmitkowski, Maciej
Lemancewicz, Adam
Motyka, Joanna
Kobus, Agnieszka
Chorąży, Monika
Paniczko, Marlena
Ławicki, Sławomir
Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_full Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_fullStr Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_full_unstemmed Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_short Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_sort plasma levels and diagnostic utility of vegf in a three-year follow-up of patients with breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624052/
https://www.ncbi.nlm.nih.gov/pubmed/34830735
http://dx.doi.org/10.3390/jcm10225452
work_keys_str_mv AT bedkowskagrazynae plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT gacutaewa plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT zbuckakretowskamonika plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT ławickipaweł plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT szmitkowskimaciej plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT lemancewiczadam plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT motykajoanna plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT kobusagnieszka plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT chorazymonika plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT paniczkomarlena plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
AT ławickisławomir plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer